Head, Lymphoma/Myeloma Service
Roswell Park Cancer Institute

Associate Professor of Medicine
School of Medicine & Biomedical Sciences
University at Buffalo

Current Program

• Monoclonal Antibodies to treat lymphomas
• Clinical research studies 

Profile

Dr. Myron S. Czuczman joined the staff of Roswell Park Cancer Institute in 1992, as attending physician, Department of Medicine, and was appointed Head of the Lymphoma/Myeloma Service in 1998. He also is an Associate Professor of Medicine at the University at Buffalo (UB) School of Medicine and Biomedical Sciences. Dr. Czuczman serves on the medical staff at Buffalo General Hospital and as an Adjunct Faculty member at D’Youville College in Buffalo, NY.

Dr. Czuczman earned his medical degree from Pennsylvania State University College of Medicine in 1985. He completed internship and residency training at Cornell’s North Shore University Hospital/Memorial Sloan-Kettering Cancer Program (1985-1988). Between 1988 and 1992, Dr. Czuczman completed a fellowship in Medical Oncology/Hematology and a senior research fellowship in Hematopoietic Cancer Immunochemistry at Memorial Sloan-Kettering Cancer Center, New York, NY. He is licensed by New York State, certified by the American Board of Medical Oncology and is a Diplomate in Internal Medicine.

Dr. Czuczman’s research interests focus on monoclonal antibodies either alone or in combination with other agents in the treatment of lymphoid neoplasms, evaluating the significance of minimal residual disease in lymphoid malignancies and study of the immunophenotype of lymphoid neoplasms by multiparameter flow cytometry. His clinical research has contributed to approval by the U.S. Food and Drug Administration of the first monoclonal therapy – Rituxan – for non-Hodgkin’s lymphoma in 1997. This also was the first new treatment developed for this disease in 10 years.

Dr. Czuczman is a member of the American Association of Cancer Research, the American Society of Hematology, the American Society of Clinical Oncology, and the American College of Physicians. He also serves on the National Comprehensive Cancer Network (NCCN) Lymphoma Guidelines Panel, the NCCN non-Hodgkin’s Lymphoma Outcomes Database Panel and the Lymphoma Committee of the Cancer and Leukemia Group B (CALGB) cooperative group.

He has authored or co-authored more than 70 journal publications, book chapters and abstracts. He is a journal reviewer for the Journal of Clinical Oncology, Clinical Cancer Research, Blood, Cancer Investigation, Annals of Hematology and American Journal of Hematology.